Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in <scp> <i>EGFR</i> </scp> ‐mutated non‐small cell lung cancer patients with <scp>T790M</scp> ‐negative or unidentified mutation
Thoracic cancer